Filippo Crea
doi : 10.1093/eurheartj/ehac202
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1601–1604
Mark Nicholls
doi : 10.1093/eurheartj/ehab634
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1605–1608
Jie Wei Zhu, Jennifer L Reed, Harriette G C Van Spall
doi : 10.1093/eurheartj/ehab846
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1609–1611
Christopher M Reid, Anushka Patel, Stephen J Nicholls, Tom Briffa On behalf of the ANZACT Executive Committee
doi : 10.1093/eurheartj/ehab753
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1612–1614
Leonarda Galiuto, Carlo Patrono
doi : 10.1093/eurheartj/ehac096
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1615–1616
Andrew Wang, Emil L Fosbøl
doi : 10.1093/eurheartj/ehab898
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1617–1625
Surgery is an effective therapy in the treatment of left-sided infective endocarditis (IE) in patients for whom antibiotic treatment alone is unlikely to be curative or may be associated with ongoing risk of complications. However, the interplay between indication for surgery, its risk, and timing is complex and there continue to be challenges in defining the effects of surgery on disease-related outcome. Guidelines published by the American College of Cardiology/American Heart Association and the European Society of Cardiology provide recommendations for the use of surgery in IE, but these are limited by a low level of evidence related to predominantly observational studies with inherent selection and survival biases. Evidence to guide the timing of surgery in IE is less robust, and predominantly based on expert consensus. Delays between IE diagnosis and recognition of an IE complication as a surgical indication and transfers to surgical centres also impact surgical timing. This comparison of the two guidelines exposes areas of uncertainty and gaps in current evidence for the use of surgery in IE across different indications, particularly related to its timing and consideration of operative risk.
Giovanni Benfari, Paul Sorajja, Giovanni Pedrazzini, Maurizio Taramasso, Mara Gavazzoni, Luigi Biasco, Benjamin Essayagh, Francesco Grigioni, Richard Bae, Christophe Tribouilloy, Jean-Louis Vanoverschelde, Hector Michelena, Vinayak N Bapat, David Vancraynest, Catherine Klersy, Moreno Curti, Prabin Thapa, Maurice Enriquez-Sarano
doi : 10.1093/eurheartj/ehab910
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1626–1635
Randomized clinical trials demonstrated transcatheter edge-to-edge repair (TEER) efficacy in improving outcome vs. medical management for functional mitral regurgitation, but limited randomized data are available for the treatment of degenerative mitral regurgitation (DMR). We aimed to compare the outcome of older patients treated with TEER vs. unoperated DMR.
Bernard Iung, Marina Urena
doi : 10.1093/eurheartj/ehac039
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1636–1638
Nirat Beohar, Gorav Ailawadi, Lak N Kotinkaduwa, Björn Redfors, Matheus Simonato, Zixuan Zhang, Loren Garrison Morgan, Esteban Escolar, Saibal Kar, David Scott Lim, Jacob M Mishell, Brian K Whisenant, William T Abraham, JoAnn Lindenfeld, Michael J Mack, Gregg W Stone
doi : 10.1093/eurheartj/ehac026
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1639–1648
Baseline renal dysfunction (RD) adversely impacts outcomes among patients with heart failure (HF) and severe secondary mitral regurgitation (MR). Heart failure and MR, in turn, accelerate progression to end-stage renal disease (ESRD), worsening prognosis. We sought to determine the impact of RD in HF patients with severe MR and the impact of transcatheter mitral valve repair (TMVr) on new-onset ESRD and the need for renal replacement therapy (RRT).
Volker Rudolph
doi : 10.1093/eurheartj/ehac084
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1649–1651
Zongtao Liu, Nianguo Dong, Haipeng Hui, Yixuan Wang, Fayun Liu, Li Xu, Ming Liu, Zhenqi Rao, Zhen Yuan, Yuqiang Shang, Jun Feng, Zhejun Cai, Fei Li
doi : 10.1093/eurheartj/ehac037
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1652–1664
Tetrahydrobiopterin (BH4) is a critical determinant of the biological function of endothelial nitric oxide synthase. The present study was to investigate the role of valvular endothelial cell (VEC)-derived BH4 in aortic valve calcification.
Simon Kraler, Vidu Garg, Alexander Akhmedov
doi : 10.1093/eurheartj/ehac050
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1665–1667
Carolina Roselli, Mengyao Yu, Victor Nauffal, Adrien Georges, Qiong Yang, Katie Love, Lu Chen Weng, Francesca N Delling, Svetlana R Maurya, Maren Schrölkamp, Jacob Tfelt-Hansen, Albert Hagège, Xavier Jeunemaitre, Stéphanie Debette, Philippe Amouyel, Wyliena Guan, Jochen D Muehlschlegel, Simon C Body, Svati Shah, Zainab Samad, Sergiy Kyryachenko, Carol Haynes, Michiel Rienstra, Thierry Le Tourneau, Vincent Probst, Ronan Roussel, Inez J Wijdh-Den Hamer, Joylene E Siland, Kirk U Knowlton, Jean Jacques Schott, Robert A Levine, Emelia J Benjamin, Ramachandran S Vasan, Benjamin D Horne, Joseph B Muhlestein, Giovanni Benfari, Maurice Enriquez-Sarano, Andrea Natale, Sanghamitra Mohanty, Chintan Trivedi, Moore B Shoemaker, Zachary T Yoneda, Quinn S Wells, Michael T Baker, Eric Farber-Eger, Hector I Michelena, Alicia Lundby, Russell A Norris, Susan A Slaugenhaupt, Christian Dina, Steven A Lubitz, Nabila Bouatia-Naji, Patrick T Ellinor, David J Milan
doi : 10.1093/eurheartj/ehac049
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1668–1680
Mitral valve prolapse (MVP) is a common valvular heart disease with a prevalence of >2% in the general adult population. Despite this high incidence, there is a limited understanding of the molecular mechanism of this disease, and no medical therapy is available for this disease. We aimed to elucidate the genetic basis of MVP in order to better understand this complex disorder.
Teresa Trenkwalder, Markus Krane
doi : 10.1093/eurheartj/ehac048
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Pages 1681–1683
Shih-Jung Jang, Ying-Hwa Chen, Ta-Chung Shen
doi : 10.1093/eurheartj/ehab824
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Page 1684
Kareem Bedeir, Robert P Robichaux, Jr, Thomas G Gleason
doi : 10.1093/eurheartj/ehab859
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Page 1685
Federica Donato, Ivo Boskoski, Giovanni Tinelli, Yamume Tshomba
doi : 10.1093/eurheartj/ehab860
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Page 1686
doi : 10.1093/eurheartj/ehac124
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Page 1635
doi : 10.1093/eurheartj/ehac119
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Page 1638
doi : 10.1093/eurheartj/ehac075
European Heart Journal, Volume 43, Issue 17, 1 May 2022, Page 1651
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟